Infection Risk During Targeted and Biologic Therapies in Rheumatoid Arthritis and Psoriatic Arthritis
An overview of the risk for infections during targeted and biological therapies in rheumatoid arthritis and psoriatic arthritis.
An overview of the risk for infections during targeted and biological therapies in rheumatoid arthritis and psoriatic arthritis.
The COVID-19 Global Rheumatology Alliance Patient Experience Survey was used to assess the effect of antimalarial drug shortages during the COVID-19 pandemic.
Treat-to-target and safe tapering strategies have been considered essential in the management of rheumatoid arthritis.
In study data presented at the 2019 ACR Annual Meeting, researchers evaluated the overall safety of upadacitinib as monotherapy and combination therapy with background disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis.
Researchers assessed the most recent safety data of synthetic and biologic disease-modifying antirheumatic drugs to inform the 2019 update of the European League Against Rheumatism recommendations for the management of rheumatoid arthritis.
Researchers aimed to determine the association of antibiotic usage and rheumatoid arthritis diagnosis and flares.
Investigators identified risk factors for repeat surgical intervention after initial arthrotomy for presumed septic arthritis of the hip.
Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.
Attaining low RA disease activity may reduce risk for serious infections.
Discontinuing methotrexate for 2 weeks following flu vaccine may improve the immunogenicity of the vaccine in patients with rheumatoid arthritis.